Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Press Releases
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société IMMUTEP LIMITED
10/13IMMUTEP : Corporate Connect - A Truly Undervalued Company
PU
10/12IMMUTEP : 2021 Annual General Meeting and Key Dates
PU
10/03IMMUTEP : to present Phase II TACTI-002 data at SITC 2021
PU
10/01IMMUTEP : to Present Phase II TACTI-002 Data at SITC 2021
AQ
09/29IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government
AQ
09/29IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government (Form 6-K)
PU
09/28IMMUTEP : Receives A$3.4 million R&D French Tax Incentive
PU
09/27IMMUTEP : to Present at Healthcare Investor Conferences
PU
09/21Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking ..
GL
09/20IMMUTEP : Maxim Group - The Case for LAG-3 is Building
PU
09/20IMMUTEP : ESMO 2021 – INSIGHT - Stratum D Poster
PU
09/02IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-..
PU
09/01IMMUTEP : PRELIMINARY FINAL REPORT (Form 6-K)
PU
09/01IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-..
PU
08/31IMMUTEP : Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
AQ
08/31IMMUTEP : S CHINESE PARTNER, EOC PHARMA, EXPANDS EFTI TRIAL PIPELINE (Form 6-K)
PU
08/30IMMUTEP : Partner, EOC Pharma, Expands Efti Trial Pipeline
PU
08/30IMMUTEP : Maxim Group - Annual FY Update; AIPAC Final Data Approaching
PU
08/27IMMUTEP : ANNOUNCES CHINESE PATENT GRANT FOR LAG-3 ANTAGONIST ANTIBODY LAG525 (Form 6-K)
PU
08/26IMMUTEP : Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
PU
08/05IMMUTEP : Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo..
AQ
08/05IMMUTEP : Reports Dosing of First Patient For Triple Combination (efti + anti-PD-1 + chemo..
PU
08/04IMMUTEP : INSIGHT-003 investigator-initiated trial - 1st patient dosed
PU
08/03IMMUTEP : Ladenburg Thalman - New Age Immune Regulator; Initiate with a Buy Rating and $8...
PU
08/02IMMUTEP : completes tranche 2 of its previously announced placement (Form 6-K)
PU
07/29IMMUTEP : Completion of Placement - Tranche 2
PU
07/26IMMUTEP : Results of EGM
PU
07/25IMMUTEP : 2021 EGM Presentation
PU
07/20IMMUTEP : Completion of Share Purchase Plan
PU
07/16IMMUTEP : Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Check..
PU
07/15IMMUTEP : Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit - poster presentation
PU
07/14IMMUTEP : Quarterly Activities Report & Appendix 4C (Form 6-K)
PU
07/13IMMUTEP : Bell Potter - Creating Value with Phase 3 around the corner – Increasing T..
PU
07/13IMMUTEP : Quarterly Activities Report
AQ
07/06IMMUTEP : receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
AQ
06/22IMMUTEP : completes a A$60 million placement to expand its clinical development and manufa..
PU
06/22IMMUTEP : to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy a..
PU
06/21IMMUTEP : Completes a A$60 Million Placement to Expand its Clinical Development and Manufa..
AQ
06/20IMMUTEP : Capital Raising Presentation
PU
06/20IMMUTEP : secures commitments for A$60 million through a two-tranche institutional placeme..
PU
06/20IMMUTEP : to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy a..
PU
06/10IMMUTEP : Alliance Global Partners - Immutep's Vindication and the Next Chapter in LAG-3 I..
PU
06/09IMMUTEP : TACTI-002 and INSIGHT Clinical Results & Update Global Webcast Slides
PU
06/09IMMUTEP : Reveals a New anti-LAG-3 Research Program (Form 6-K)
PU
06/07IMMUTEP : Reveals a New anti-LAG-3 Research Program
PU
06/07IMMUTEP : Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy,..
PU
06/07IMMUTEP : Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, ..
PU
06/05IMMUTEP : Goetzpartners securities - Efti combos move towards centre stage at ASCO
PU
06/04IMMUTEP : Maxim Group - ASCO Updates, LAG-3 is Emerging – Shares RemainUndervalued
PU
06/04IMMUTEP : ASCO 2021 - TACTI-002 Poster for NSCLC
PU
06/04IMMUTEP : ASCO 2021 - TACTI-002 Poster for HNSCC
PU
06/04IMMUTEP : ASCO 2021 - INSIGHT Poster
PU
06/04IMMUTEP : Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy,..
AQ
06/04Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti,..
GL
06/03IMMUTEP : SECURES SECOND EUROPEAN PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, I..
PU
06/02IMMUTEP : enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Th..
PU
06/01IMMUTEP : Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, I..
PU
05/31IMMUTEP : Enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Th..
PU
05/27IMMUTEP : GRANTED CHINESE PATENT FOR EFTILAGIMOD ALPHA IN CHEMO-IMMUNOTHERAPY COMBINATION ..
PU
05/25IMMUTEP : Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
PU
05/24IMMUTEP : to Present at the Jefferies Virtual Healthcare Conference
PU
05/21IMMUTEP : announces publication of TACTI-002 and INSIGHT-004 abstracts for ASCO 2021 Annua..
PU
05/20IMMUTEP : Goetzpartners securities - BMS shows LAG-3 - PD-1 combo boosts PFS in melanoma
PU
05/20IMMUTEP : Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annua..
AQ
05/12IMMUTEP : OPERATIONAL UPDATE (Form 6-K)
PU
05/06IMMUTEP : Operational Update
PU
05/02IMMUTEP : Corporate Connect - Efti a highly sought after compound for mono & combo Cancer ..
PU
04/30IMMUTEP : To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discu..
PU
04/30IMMUTEP : Corporate Connect - Efti a highly sort after compound for mono & combo Cancer tr..
PU
04/29IMMUTEP : Corporate Connect - Efti a highly sought after compound for mono & combo Cancer ..
PU
04/28Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Disc..
GL
04/19IMMUTEP : receives A$1,155,055 R&D Tax Incentive
AQ
04/19IMMUTEP : Quarterly Activities Report
AQ
04/18IMMUTEP : Quarterly Activities Report & Appendix 4C
PU
04/16IMMUTEP : Receives A$1,155,055 R&D Tax Incentive
PU
1  2  3  4Next
Upcoming event on IMMUTEP LIMITED
Upcoming sector events